Arrowhead Pharmaceuticals (ARWR) shares are in focus after the company released two-year open-label extension data for plozasiran, showing large and durable triglyceride reductions with a consistent safety profile in patients with hypertriglyceridemia.
See our latest analysis for Arrowhead Pharmaceuticals.
The new plozasiran data arrived after a mixed stretch for Arrowhead's share price, with a 7 day share price return of 5.62% offsetting recent declines. Over the past year, the total shareholder return of more than 4x suggests strong underlying momentum.
If this kind of clinical progress has your attention, it may be worth widening your search using our screener of 36 healthcare AI stocks for more potential opportunities in data driven healthcare.
With Arrowhead valued at about US$8.5b, recent revenue of roughly US$1.1b and a share price of US$61.03 that sits below some analyst targets, investors may ask whether there is still a buying opportunity or whether the market is already pricing in future growth.
Most Popular Narrative: 4.8% Undervalued
Arrowhead's widely followed narrative pegs fair value at about $64.08 per share, only modestly above the last close at $61.03, which keeps expectations tight.
Analysts have raised their price targets on Arrowhead Pharmaceuticals by roughly $6 to the mid $40s to low $60s range, citing the FDA approval of Redemplo, a strengthened commercial outlook in familial chylomicronemia syndrome and sHTG, and underappreciated long term cost and margin advantages.
Curious what justifies a higher fair value even as long term revenue growth assumptions soften? The narrative leans heavily on future margins, premium multiples and a bold earnings path.
Result: Fair Value of $64.08 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to weigh reliance on collaboration payments and the risk that key late stage trials or regulatory decisions do not go Arrowhead's way.
Find out about the key risks to this Arrowhead Pharmaceuticals narrative.
Another View: Market Ratios Flash A Different Signal
While the narrative fair value of $64.08 points to Arrowhead as modestly undervalued, the current P/E of 42.3x tells a different story. That multiple sits well above the US Biotechs average of 15.2x and the peer average of 20.2x, and more than doubles the 17.4x fair ratio. This suggests valuation risk if sentiment cools. How much weight do you put on earnings based multiples versus long term narratives?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mix of enthusiasm and caution in this story, it makes sense to look at the numbers yourself and move before narratives shift. To see what optimism is grounded in, review the company's 2 key rewards.
Looking for more investment ideas?
If Arrowhead has you thinking bigger about your portfolio, do not stop here. Use targeted stock lists to quickly surface quality ideas that match your style.
- Target higher potential returns by scanning for companies that look attractively valued through the 59 high quality undervalued stocks.
- Prioritise resilience by focusing on companies with stronger finances using the solid balance sheet and fundamentals stocks screener (40 results).
- Hunt for under the radar opportunities that the market might be overlooking with the screener containing 25 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com